Specialty advisory firm Accordant Advisory Group Inc provides strategic consulting and transaction advisory to healthcare and life sciences clients, focusing on M&A, corporate finance, and commercial strategy. The firm positions itself as a boutique advisor serving private equity sponsors, corporate acquirers and growth-stage companies with due diligence, valuation and integration planning. Fee-for-service and success-based engagements support mid-market deals and cross-border transactions, leveraging senior industry operators to bridge clinical, regulatory and commercial value creation.
Specialty advisory firm Accordant Advisory Group Inc provides strategic consulting and transaction advisory to healthcare and life sciences clients, focusing on M&A, corporate finance, and commercial strategy. The firm positions itself as a boutique advisor serving private equity sponsors, corporate acquirers and growth-stage companies with due diligence, valuation and integration planning. Fee-for-service and success-based engagements support mid-market deals and cross-border transactions, leveraging senior industry operators to bridge clinical, regulatory and commercial value creation.
Operates as a sector-focused strategic investor/advisor that prioritizes healthcare and life-sciences opportunities where clinical, regulatory and commercial gaps create mispriced risk. Emphasizes transaction-led value creation: rigorous operational and regulatory due diligence, conservative underwriting, and integration-oriented capital allocation to de-risk mid-market M&A. Targets sponsor-backed and growth-stage assets with three-to-seven year horizons, favoring scalable commercial models and differentiated clinical assets. Risk discipline centers on regulatory pathway clarity, measurable commercial milestones and staged, fee- and success-linked deployment to align incentives and preserve downside.
Operates as a sector-focused strategic investor/advisor that prioritizes healthcare and life-sciences opportunities where clinical, regulatory and commercial gaps create mispriced risk. Emphasizes transaction-led value creation: rigorous operational and regulatory due diligence, conservative underwriting, and integration-oriented capital allocation to de-risk mid-market M&A. Targets sponsor-backed and growth-stage assets with three-to-seven year horizons, favoring scalable commercial models and differentiated clinical assets. Risk discipline centers on regulatory pathway clarity, measurable commercial milestones and staged, fee- and success-linked deployment to align incentives and preserve downside.
| Trades 945 | Longs Won 512/945 54% | Profit Factor 2.82 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $258,961.66 |
| Average Win $86,647.63 | Best Trade (Jul 10) $3.81M | Sharpe Ratio -11.47 |
| Average Loss -$36,368.33 | Worst Trade (Sep 30) -$1.29M | Z-Score 0.35 (27.18%) |
| Commissions $0 | Avg. Trade Length 10m | Expectancy $30,281.59 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 3,922 | 3,529 | 3,137 | 2,745 | 2,353 | 1,961 | 1,569 | 1,176 | 784 | 392 |